95 related articles for article (PubMed ID: 16713265)
1. 5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity.
Carmi C; Cavazzoni A; Zuliani V; Lodola A; Bordi F; Plazzi PV; Alfieri RR; Petronini PG; Mor M
Bioorg Med Chem Lett; 2006 Aug; 16(15):4021-5. PubMed ID: 16713265
[TBL] [Abstract][Full Text] [Related]
2. 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line.
Zuliani V; Carmi C; Rivara M; Fantini M; Lodola A; Vacondio F; Bordi F; Plazzi PV; Cavazzoni A; Galetti M; Alfieri RR; Petronini PG; Mor M
Eur J Med Chem; 2009 Sep; 44(9):3471-9. PubMed ID: 19268405
[TBL] [Abstract][Full Text] [Related]
3. Receptor-guided alignment-based comparative 3D-QSAR studies of benzylidene malonitrile tyrphostins as EGFR and HER-2 kinase inhibitors.
Kamath S; Buolamwini JK
J Med Chem; 2003 Oct; 46(22):4657-68. PubMed ID: 14561085
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
[TBL] [Abstract][Full Text] [Related]
5. Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrophostins: potent inhibitors of EGF receptor tyrosine kinase in vitro.
Gazit A; Osherov N; Gilon C; Levitzki A
J Med Chem; 1996 Dec; 39(25):4905-11. PubMed ID: 8960549
[TBL] [Abstract][Full Text] [Related]
6. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
7. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
8. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
[TBL] [Abstract][Full Text] [Related]
9. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
10. Discovering novel 3-nitroquinolines as a new class of anticancer agents.
Li HH; Huang H; Zhang XH; Luo XM; Lin LP; Jiang HL; Ding J; Chen KX; Liu H
Acta Pharmacol Sin; 2008 Dec; 29(12):1529-38. PubMed ID: 19026174
[TBL] [Abstract][Full Text] [Related]
11. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
Domarkas J; Dudouit F; Williams C; Qiyu Q; Banerjee R; Brahimi F; Jean-Claude BJ
J Med Chem; 2006 Jun; 49(12):3544-52. PubMed ID: 16759097
[TBL] [Abstract][Full Text] [Related]
12. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells.
Kim SH; Song YC; Kim SH; Jo H; Song YS
Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115
[TBL] [Abstract][Full Text] [Related]
13. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors.
Lee YS; Seo SH; Yang BS; Lee JY
Arch Pharm (Weinheim); 2005 Oct; 338(10):502-5. PubMed ID: 16211656
[TBL] [Abstract][Full Text] [Related]
15. In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells.
Cavasotto CN; Ortiz MA; Abagyan RA; Piedrafita FJ
Bioorg Med Chem Lett; 2006 Apr; 16(7):1969-74. PubMed ID: 16413185
[TBL] [Abstract][Full Text] [Related]
16. S-Nitrosylation of the epidermal growth factor receptor: a regulatory mechanism of receptor tyrosine kinase activity.
Murillo-Carretero M; Torroglosa A; Castro C; Villalobo A; Estrada C
Free Radic Biol Med; 2009 Feb; 46(4):471-9. PubMed ID: 19056486
[TBL] [Abstract][Full Text] [Related]
17. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
Lin R; Johnson SG; Connolly PJ; Wetter SK; Binnun E; Hughes TV; Murray WV; Pandey NB; Moreno-Mazza SJ; Adams M; Fuentes-Pesquera AR; Middleton SA
Bioorg Med Chem Lett; 2009 Apr; 19(8):2333-7. PubMed ID: 19286381
[TBL] [Abstract][Full Text] [Related]
19. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
20. Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.
Waterson AG; Stevens KL; Reno MJ; Zhang YM; Boros EE; Bouvier F; Rastagar A; Uehling DE; Dickerson SH; Reep B; McDonald OB; Wood ER; Rusnak DW; Alligood KJ; Rudolph SK
Bioorg Med Chem Lett; 2006 May; 16(9):2419-22. PubMed ID: 16483772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
